Nina S. Kjellson Sells 3,993 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Nina S. Kjellson sold 3,993 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total value of $65,325.48. Following the sale, the director now owns 3,707,420 shares of the company’s stock, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $15.80 on Thursday. Tyra Biosciences, Inc. has a 52 week low of $12.34 and a 52 week high of $29.60. The firm has a 50-day moving average price of $15.38 and a two-hundred day moving average price of $19.17. The firm has a market cap of $799.48 million, a price-to-earnings ratio of -9.81 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, sell-side analysts forecast that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

TYRA has been the subject of a number of recent research reports. UBS Group initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target for the company. Wedbush restated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Friday, October 25th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, January 13th. Finally, Bank of America raised Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and a consensus price target of $30.50.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new position in Tyra Biosciences during the third quarter valued at about $24,994,000. Perceptive Advisors LLC boosted its stake in Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after acquiring an additional 338,208 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in shares of Tyra Biosciences during the 2nd quarter valued at approximately $4,232,000. Ensign Peak Advisors Inc purchased a new stake in shares of Tyra Biosciences during the 2nd quarter worth approximately $3,047,000. Finally, American Century Companies Inc. increased its stake in shares of Tyra Biosciences by 582.9% during the 2nd quarter. American Century Companies Inc. now owns 170,283 shares of the company’s stock worth $2,723,000 after purchasing an additional 145,346 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.